Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial

• Main Authors: Rui Fang (Author), Hua Hu (Author), Yue Zhou (Author), Shanshan Wang (Author), Zhigang Mei (Author), Ruining She (Author), Xiwen Peng (Author), Qiling Jiang (Author), Xiangyuan Wang (Author), Le Xie (Author), Hongyuan Lin (Author), Pan Meng (Author), Kun Zhang (Author), Wei Wang (Author), Yao Xie (Author), Litao Liu (Author), Jiao Tong (Author), Dahua Wu (Author), Yunhua Luo (Author), Chang Liu (Author), Yifang Lu (Author), Shangzhen Yu (Author), Shaowu Cheng (Author), Linyong Xu (Author), Zhuyuan Fang (Author), Hongcai Shang (Author), Jinwen Ge (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Hypertensive cerebral small vessel disease (HT-CSVD) is a cerebrovascular clinical, imaging and pathological syndrome caused by hypertension (HT). The condition manifests with lesions in various vessels including intracranial small/arterioles, capillaries, and small/venules. Hypertensive...